pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastische middelen - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed teva 100 mg inf. opl. (pdr., conc.) i.v. flac.
teva pharma belgium sa-nv - pemetrexeddinatrium - eq. pemetrexed 100 mg - poeder voor concentraat voor oplossing voor infusie - 100 mg - pemetrexeddinatrium - pemetrexed
pemetrexed teva 500 mg inf. opl. (pdr., conc.) i.v. flac.
teva pharma belgium sa-nv - pemetrexeddinatrium - eq. pemetrexed 500 mg - poeder voor concentraat voor oplossing voor infusie - 500 mg - pemetrexeddinatrium - pemetrexed
pemetrexed teva 1000 mg inf. opl. (pdr., conc.) i.v. flac.
teva pharma belgium sa-nv - pemetrexeddinatrium - eq. pemetrexed 1000 mg - poeder voor concentraat voor oplossing voor infusie - 1000 mg - pemetrexeddinatrium - pemetrexed
pemetrexed waverley 100 mg inf. opl. (pdr., conc.) i.v. flac.
waverley pharma europe ltd. - pemetrexeddinatrium - eq. pemetrexed 100 mg - poeder voor concentraat voor oplossing voor infusie - 100 mg - pemetrexeddinatrium - pemetrexed
pemetrexed waverley 500 mg inf. opl. (pdr., conc.) i.v. flac.
waverley pharma europe ltd. - pemetrexeddinatrium - eq. pemetrexed 500 mg - poeder voor concentraat voor oplossing voor infusie - 500 mg - pemetrexeddinatrium - pemetrexed
pemetrexed bioorganics 1000 mg inf. opl. (pdr., conc.) i.v. flac.
bioorganics b.v. - pemetrexeddinatriumhemipentahydraat - eq. pemetrexeddinatrium 1000 mg - poeder voor concentraat voor oplossing voor infusie - 1000 mg - pemetrexeddinatriumhemipentahydraat - pemetrexed
pemetrexed bioorganics 500 mg inf. opl. (pdr., conc.) i.v. flac.
bioorganics b.v. - pemetrexeddinatriumhemipentahydraat - eq. pemetrexeddinatrium 500 mg - poeder voor concentraat voor oplossing voor infusie - 500 mg - pemetrexeddinatriumhemipentahydraat - pemetrexed
pemetrexed bioorganics 100 mg inf. opl. (pdr., conc.) i.v. flac.
bioorganics b.v. - pemetrexeddinatriumhemipentahydraat - eq. pemetrexed 100 mg - poeder voor concentraat voor oplossing voor infusie - 100 mg - pemetrexeddinatriumhemipentahydraat - pemetrexed
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastische middelen - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.